RESEARCH CENTER – CLINICAL TRIALS
ACCESS TO THE LATEST
TREATMENTS
Oregon Urology Institute is committed to advancing the standard of care in treating urological disorders and cancers. To achieve this, we are deeply involved in research at our urology clinic. This gives our patients access to experimental procedures and treatments that wouldn’t otherwise be available.
If you’d like to join one of the trials at our urology clinic, your doctor can help determine if you’re a candidate. Qualified candidates will be informed about potential risks and benefits. Our clinical trial participants are carefully monitored, and you can opt out at any time.
CURRENTLY
ENROLLING
Here are trials we’re currently conducting at our urology clinic. Ask your doctor for more information if you’re interested in participating.
PROSTATE CANCER–DAROL
Study Type: Observational
Study Design:
- Observational Model: Cohort
- Time Perspective: Prospective
- Estimated Enrollment: 1000 participants
Official Title:Darolutamide Observational Study in Non-metastatic Castration-resistant
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–VERACITY
Study Type: Interventional (Clinical Trial)
Study Design:
- Estimated Enrollment : 245 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Intervention Model Description: This randomized, open-label, active-control clinical study consists of two treatment arms:VERU-111 (Sabizabulin) treated group, and Control treated group. Subjects will be randomized in a 2:1 fashion.
- Masking: Single (Outcomes Assessor)
- Masking Description: Central reader for scans will be blinded
- Primary Purpose: Treatment
Official Title:VERACITY – Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
For more information on this study, visit clinicaltrials.gov
BLADDER CANCER-KN676
Study Type: Interventional (Clinical Trial)
Study Design:
- Estimated Enrollment: 1045 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676)
For more information on this study, visit clinicaltrials.gov
BLADDER CANCER-Nucleix
Study Type: Observational
Study Design:
- This is a multicenter, prospective, observational study to support the CLIA accreditation of Nucleix’s lab by collecting urine samples from subjects suspected for bladder cancer.
This is a single visit study. Each subject, approximately 300, will sign the informed consent and provide voided urine sample (at least 40ml). Demography and pathology information will be collected for each subject.
Study Rationale:
- Urothelial cell carcinoma (UCC) is the 6th most common cancer in the United States affecting both men and women. Both the diagnosis and surveillance of UCC requires cystoscopic evaluation and imaging studies making UCC one of the most time intensive cancers to manage. There is a significant need for additional urine-based biomarkers to assist in identifying individuals at greatest risk of UCC recurrence to provide timely and appropriate urologic evaluation..
Official Title: Urine Samples Collection to Support the Bladder EpiCheck Analytical Validation Studies (Bladder EpiCheck-USLAB-01)
ONGOING STUDIES
NOT ENROLLING
PROSTATE CANCER–ATLAS
Study Type: Interventional
Study Design:
- Allocation: Randomized
- Actual Enrollment: 1503 Participants
- Intervention Model: Parallel Assignment
- Masking: Double Blind (Subject, Investigator)
- Primary Purpose: Treatment
Official Title: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy.
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–APA RP
Study Type: Interventional (Clinical Trial)
Study Design:
- Estimated Enrollment: 94 participants
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Official Title: A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-naïve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases.
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–EMBARK
Study Type: Interventional
Study Design:
- Actual Enrollment: 1068 participants
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy)
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER- PROVENT
Study Type:
Interventional
Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be randomized 2:1 to the sipuleucel-T arm or the control arm.Subjects randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals. Subjects randomized to the control arm will be followed on AS as standard of care described in the schedule of events.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title:
A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered To Patients On Active Surveillance For Newly Diagnosed Prostate Cancer
For more information on this study, visit clinicaltrials.gov
URETHRAL STRICTURE–ROBUST III
Study Type: Interventional
Study Design:
Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment
Official Title:
ROBUST III – Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease – A Randomized Control Trial
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–SAFELY
Study Design:
- Observational Model: Cohort
- Time Perspective: Prospective
- Estimated Enrollment: 600 participants
- Target Follow-Up Duration: 10 Years
- Official Title: A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–TAK-RAD
Study Type:
Interventional
Study Design:
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
For more information on this study, visit clinicaltrials.gov
PROSTATE CANCER–ULYSSES
Study Type:
Interventional
Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title:
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
For more information on this study, visit clinicaltrials.gov
CONTACT US
2400 HARTMAN LANE,
SPRINGFIELD, OR 97477
PHONE: 541.334.3350
TOLL FREE: 1.800.246.9925
FAX: 541.343.3459
FIND US
JOIN OUR TEAM
